{"schema_version":"secwatch.filing_event.v1","accession":"0001722482-24-000084","form_type":"8-K","ticker":"AVTR","cik":"0001722482","company_name":"Avantor, Inc.","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.741478+00:00","generated_at":"2026-06-04T01:51:37.165257+00:00","sec_items":["1.01","2.03","5.02","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avantor refinances $772M term loans at lower rate; former EVP to advise","bullets":["Refinanced $772.4M Incremental B-6 Dollar Term Loans at SOFR + 2.00% (down from +2.25% on prior loans).","New loans mature Nov 6, 2027, same maturity as refinanced B-5 loans; proceeds used to repay existing B-5 term loans.","Dr. Gerard Brophy, former EVP Biopharma Production, gets consulting deals: $180K/yr cash + $25K/yr + $50K RSU for SAB chair role through Feb 2027.","Consulting agreements include noncompetition, nonsolicitation, and IP assignment provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001722482-24-000084","json":"https://secwatch.observer/filing/0001722482-24-000084.json","markdown":"https://secwatch.observer/filing/0001722482-24-000084.md","text":"https://secwatch.observer/filing/0001722482-24-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1722482/000172248224000084/0001722482-24-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1722482/000172248224000084/avtr-20240402.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:51:37.165257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b067456a25ed87a823324988433210d2c903ddd2","claim":"Avantor, Inc. incurred term loan of $772,396,875.00 with Goldman Sachs Bank USA at SOFR plus a spread of 2.00% per annum maturing November 6, 2027.","evidence_excerpt":"the Borrower obtained a $772,396,875.00 tranche of senior secured U.S. dollar term loans (the “Incremental B-6 Dollar Term Loans”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1722482/000172248224000084/0001722482-24-000084-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$772,396,875.00"},{"label":"Counterparty","value":"Goldman Sachs Bank USA"},{"label":"Rate","value":"SOFR plus a spread of 2.00% per annum"},{"label":"Maturity","value":"November 6, 2027"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"fd5cd2a7235b3ddb35cdeb40799da4b3fea94c8a","claim":"Avantor, Inc. amended Amendment No. 12 with Goldman Sachs Bank USA, as administrative agent and collateral agent valued at $772,396,875.00 (effective 2024-04-02).","evidence_excerpt":"On April 2, 2024 (the “Effective Date”), Avantor, Inc.’s (the “Company”) wholly owned subsidiary, Avantor Funding, Inc. (the “Borrower”), entered into Amendment No. 12 (the “Credit Agreement Amendment”) to Credit Agreement, dated as of November 21, 2017","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1722482/000172248224000084/0001722482-24-000084-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Goldman Sachs Bank USA, as administrative agent and collateral agent"},{"label":"Value","value":"$772,396,875.00"},{"label":"Effective","value":"2024-04-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}